The inauguration of a new government brings hope and anticipation to each and every industry. The same goes for multinational pharmaceutical companies.

In the pharmaceutical industry, hopes are rising for the expanded eligibility of the pharmacoeconomic evaluation exemption scheme. Although many agendas remain in need of resolution, such as improvement of drug prices for each indication and the pre-listing post-evaluation scheme, etc., the industry believes the improvement of the PE exemption system is most realistic.

This seems plausible from the third person's perspective as well. In fact, Yoon Suk-Yeol’s administration plans to promote the accelerated listing of anticancer drugs an